Research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging describes a new class of radiopharmaceuticals, named radiohybrids, that offer a fresh perspective on cancer imaging and radioligand therapy.
Source: News Medical, https://www.news-medical.net/